NO20064031L - Esterderivater av thein og deres terapeutiske anvendelse - Google Patents

Esterderivater av thein og deres terapeutiske anvendelse

Info

Publication number
NO20064031L
NO20064031L NO20064031A NO20064031A NO20064031L NO 20064031 L NO20064031 L NO 20064031L NO 20064031 A NO20064031 A NO 20064031A NO 20064031 A NO20064031 A NO 20064031A NO 20064031 L NO20064031 L NO 20064031L
Authority
NO
Norway
Prior art keywords
alkyl
thein
therapeutic use
optionally substituted
ester derivatives
Prior art date
Application number
NO20064031A
Other languages
English (en)
Inventor
Andrew Douglas Baxter
Andrea Walmsley
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of NO20064031L publication Critical patent/NO20064031L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C66/00—Quinone carboxylic acids
    • C07C66/02—Anthraquinone carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Forbindelser som kan ha anti-inflammatorisk aktivitet har den generelle formel (I): hvor Xi er H eller CORog Xer H eller CORmen X! og Xer ikke begge H; Rog Rer like eller forskjellige og er hver C.alkyl substituert med Reller en fire- til syv-leddet ring som eventuelt kan være substituert med Rg og kan inneholde ett eller flere ytterligere heteroatomer valgt fra O, S(0)og NR,; Rer F, CF, OR, NRReller SiO^ R, ; R, Rog Rer like eller forskjellige og er hver H eller Cw alkyl eventuelt substituert med Reller NRRer en C.heterocykloalkylring inneholdende ett eller flere heteroatomer valgt fra O, NRgg S(0); hver n er 0-2; Rer C^ alkyl; Rg er som definert for Reller Cw alkyl eventuelt substituert med Reller halogen; og Rer H eller Cw alkyl; eller et salt, solvat eller hydrat derav.
NO20064031A 2004-03-04 2006-09-07 Esterderivater av thein og deres terapeutiske anvendelse NO20064031L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0404953.2A GB0404953D0 (en) 2004-03-04 2004-03-04 Pro-drugs
PCT/GB2005/000832 WO2005085170A1 (en) 2004-03-04 2005-03-04 Ester derivatives of rhein and their therapeutic use

Publications (1)

Publication Number Publication Date
NO20064031L true NO20064031L (no) 2006-09-15

Family

ID=32088751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064031A NO20064031L (no) 2004-03-04 2006-09-07 Esterderivater av thein og deres terapeutiske anvendelse

Country Status (14)

Country Link
US (1) US7728035B2 (no)
EP (1) EP1723097A1 (no)
JP (1) JP4478713B2 (no)
KR (1) KR20070010142A (no)
CN (1) CN1938258A (no)
AU (1) AU2005219642B2 (no)
BR (1) BRPI0508352A (no)
CA (1) CA2558082A1 (no)
GB (1) GB0404953D0 (no)
IL (1) IL177752A0 (no)
MX (1) MXPA06010058A (no)
NO (1) NO20064031L (no)
WO (1) WO2005085170A1 (no)
ZA (1) ZA200607386B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622479D0 (en) * 2006-11-10 2006-12-20 Sosei R & D Ltd Novel salts and their therapeutic use
CN101735271A (zh) * 2008-11-05 2010-06-16 上海慈瑞医药科技有限公司 具有趋骨性的双膦酸大黄酸醚衍生物及其制备方法
CN102225896B (zh) * 2011-04-07 2013-10-30 栗进才 大黄酸的醚衍生物以及它们的治疗用途
CN102552430A (zh) * 2011-12-03 2012-07-11 彭旦明 一种抑制瘢痕的有效部位群及其制备方法
CN102603575B (zh) * 2012-01-04 2014-08-13 丛晓东 大精酸共晶物、其制备方法、纯化方法及其在制备治疗糖尿病并发症药物中的应用
WO2014011753A2 (en) * 2012-07-10 2014-01-16 Georgia State University Research Foundation, Inc. Anthraquinone analogs and methods of making and using thereof
CN104547207A (zh) * 2015-01-29 2015-04-29 陈文斌 消除陈旧性疤痕的中药外敷制剂及制备方法
MX2018002049A (es) * 2015-08-17 2018-06-15 Twi Biotechnology Inc Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
CN106619503B (zh) * 2016-09-23 2019-09-13 辽宁大学 一种大黄酸酰胺类衍生物纳米混悬剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) * 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
JPS58225015A (ja) * 1983-02-25 1983-12-27 プロツタ−・エス・ピ−・エ− 硬化症治療薬
IT1283772B1 (it) * 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di reina e diacereina
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree

Also Published As

Publication number Publication date
EP1723097A1 (en) 2006-11-22
GB0404953D0 (en) 2004-04-07
ZA200607386B (en) 2008-05-28
AU2005219642B2 (en) 2009-04-23
JP4478713B2 (ja) 2010-06-09
JP2007526293A (ja) 2007-09-13
CA2558082A1 (en) 2005-09-15
CN1938258A (zh) 2007-03-28
AU2005219642A1 (en) 2005-09-15
WO2005085170A1 (en) 2005-09-15
US7728035B2 (en) 2010-06-01
IL177752A0 (en) 2006-12-31
KR20070010142A (ko) 2007-01-22
US20070185036A1 (en) 2007-08-09
BRPI0508352A (pt) 2007-07-31
MXPA06010058A (es) 2007-05-10

Similar Documents

Publication Publication Date Title
NO20064031L (no) Esterderivater av thein og deres terapeutiske anvendelse
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
ATE517882T1 (de) Chinolinderivate
NO20081970L (no) Sulfonamidderivat med PGD2-reseptorantagonistaktivitet
NO20074620L (no) Spiroheterocykliske forbindelser og deres anvendelse som medikamenter
DK1539753T3 (da) Pyrazolo(3,4B9pyridin-forbindelser og deres anvendelse som phosphodiesterase-inhibitorer
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
NO20053133L (no) Kjemiske forbindelser.
EA202192019A1 (ru) Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
ATE556058T1 (de) 1-(2h)-isochinolonderivat
NO20073465L (no) Benzotiazol-derivater
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20064297L (no) Aminoalkoholforbindelse
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
NO20062370L (no) Amidderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application